| Identification | Back Directory | [Name]
Nicaraven | [CAS]
79455-30-4 | [Synonyms]
AVS
NICARAVEN
Nicaraven, >98%
Nicaraven, 79455-30-4
1,2-bis(nicotinamido)propane
n,n'-propylenedinicotinamide
N,N'-Propylenebisnicotinamide
N,N'-Propylenebis(nicotinamide)
N,N'-(Propane-1,2-diyl)dinicotinaMide
N,N'-(1-Methylethylene)bisnicotinamide
N,N'-(1-Methylethylene)bis(pyridine-3-carboxamide)
3-Pyridinecarboxamide,N,N'-(1-methyl-1,2-ethanediyl)bis-
N-{1-[(pyridin-3-yl)formamido]propan-2-yl}pyridine-3-carboxamide
Nicaraven N,N'-Propylenedinicotinamide | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C15H16N4O2 | [MDL Number]
MFCD00411904 | [MOL File]
79455-30-4.mol | [Molecular Weight]
284.31 |
| Chemical Properties | Back Directory | [Melting point ]
156-157° | [Boiling point ]
635.9±40.0 °C(Predicted) | [density ]
1.213±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMF: 5 mg/ml; DMSO: 10 mg/ml; Ethanol: 2 mg/ml; PBS (pH 7.2): 2 mg/ml | [form ]
A crystalline solid | [pka]
12.93±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Nicaraven is an antioxidant that exhibits hydroxyl radical scavenging activity in vitro.1 Nicaraven (1-3 mg/kg per min, i.v.) reduces occurrence of chronic cerebral vasospasms in a dose-dependent manner in a canine model of subarachnoid hemorrhage. In a canine model of warm hepatic ischemia and reperfusion injury, nicaraven (2 mg/kg per min, i.v.) reduces liver enzyme release and inhibits lipid peroxidation and neutrophil infiltration in the liver.2 Nicaraven (100 mg/kg per day, i.p.) also decreases plasma levels of the inflammatory cytokines Il-6 and Tnf-α and the urinary levels of 8-oxo-2''-deoxyguanosine, a marker of DNA oxidation, in a mouse model of radiation-induced injury.3 | [Uses]
Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger. | [in vivo]
Nicaraven inhibits lipid peroxidation in the liver, improves hepatic and systemic hemodynamics and energy metabolism, and suppresses liver enzyme release, endothelin-1 elevation in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver[1]. Nicaraven increases the number of c-kit(+) stem/progenitor cells in bone marrow and peripheral blood, with a recovery rate around 60-90% of age-matched non-irradiated healthy mice. The potency of colony forming from hematopoietic stem/progenitor cells as indicator of function is completely protected with nicaraven treatment[2]. Administration of nicaraven significantly increases the number, improves the colony-forming capacity, and decreases the DNA damage of hematopoietic stem/progenitor cells. The urinary levels of 8-oxo-2′-deoxyguanosine, a marker of DNA oxidation, are significantly lower in mice that are given nicaraven compared with those that receive a placebo. The administration of nicaraven significantly decreases the levels of the inflammatory cytokines IL-6 and TNF-α in the plasma of mice[3]. | [References]
[1] Komiya T, et al. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. DOI:10.1097/00002826-199901000-00003
[2] Yokota R, et al. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. DOI:10.1067/msy.2000.105864
[3] Ali H, et al. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. DOI:10.1016/j.bbrc.2014.08.112
[4] Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice. PLoS One. 2013;8(3):e60023. DOI:10.1371/journal.pone.0060023 |
|
|